Table 3.
Response rates to donor leukocyte infusion in chronic lymphocytic leukemia; selected studies.
| Series | Patients receiving DLI (n) | Indication for DLI following HSCT | Patients with pre-DLI chemotherapy or rituximab (n) | Response rate (n pts CR /n pts PR) |
|---|---|---|---|---|
| Marks et al. [2002] | 8 | Persistent, progressive, or relapsed disease | 12.5% (0 CR/1 PR) | |
| Ritgen et al. [2004] | 3 | MRD by IgH RQ-PCR | 0 | 67% (2 CR/0 PR) |
| Russell et al. [2005] | 4 | 2 pts with persistent disease 2 pts with relapsed disease |
0 | 75% (3 CR/0 PR) |
| Hoogendoorn et al. [2007] | 12 | 5 pts with persistent disease 7 pts with progressive disease |
33% (4 CR/0 PR) | |
| Sorror et al. [2005] | 6 | Progressive disease | 4 | 17% (1 CR/0 PR) |
| Khouri et al. [2004] | 10 | Persistent disease | 8 | 90% (7 CR/2 PR) |
| Bloor et al. [2008] | 6 | 3 pts with progressive disease 3 pts with mixed chimerism |
1 | 83% (5 CR/0 PR) |
| Schetelig et al. [2003] | 6 | Progressive disease | 0 | 17% (1 CR/0 PR) |
| Delgado et al. [2006] | 11 | Relapsed or progressive disease | 6 | 27% (3 CR/0 PR) |
CR, complete remission; DLI, donor leukocyte infusion; HSCT, allogeneic hematopoietic stem-cell transplantation; IgH RQ-PCR, immunoglobulin heavy chain real-time quantitative polymerase chain reaction; MRD, minimal residual disease; PR, partial response; pts, patients.